Skip to main content
LZAGF logo

Lonza Group AG (LZAGF) Stock Price & Analysis

Lonza Group AG (LZAGF) — price $787.33 (-3.45%), as of the Nov 19, 2026 trading session; market cap $55.0B.

Educational signal · not a buy or sell recommendation · How to read this

$787.33 −$28.17 (-3.45%) Market Cap $55.0B

Lonza Group AG · LZAGF · Healthcare · Biotechnology

Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$787.33
Change on the day-3.45%
52-week range$565.14–$841.45
Market capitalisation$55.0B—
Price / earnings (trailing)41.62
Shares traded on the day78
Beta (volatility vs the S&P 500)0.84

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $565, high $811, latest $787. $811 $565 high $811 Oct 17, 2025 Nov 19, 2026 · $787 $712Oct 17, 2025$705Oct 31, 2025$705Nov 14, 2025$675Nov 28, 2025$643Dec 12, 2025$669Dec 26, 2025$700Jan 9, 2026$715Jan 23, 2026$681Feb 6, 2026$695Feb 20, 2026$661Mar 6, 2026$565Mar 20, 2026$647Apr 2, 2026$666Apr 17, 2026$619May 1, 2026$598May 15, 2026$651May 29, 2026$617Jun 12, 2026$668Jun 26, 2026$731Jul 10, 2026$675Jul 24, 2026$712Aug 7, 2026$741Aug 21, 2026$705Sep 4, 2026$667Sep 18, 2026$660Oct 2, 2026$730Oct 16, 2026$771Oct 30, 2026$790Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Lonza Group AG (LZAGF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Negative
Debt/Equity Neutral
ROE Neutral
Gross Margin Neutral

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Lonza Group AG (LZAGF), and what does it report?

Short answer

Lonza Group AG, established in 1897 and based in Basel, Switzerland, is a global enterprise that furnishes critical products and services to the pharmaceutical, biotechnology, and nutrition sectors. Lonza Group AG (LZAGF) is classified as Healthcare / Biotechnology. Headquarters: Muenchensteinerstrasse 38, Basel, BS, 4002, CH. It employs 17,995 people. In Q2 FY2026 it reported revenue of CHF 3.36B and net income of CHF 588M. The market values it at $55.0B.

2 · Latest results

What do the latest results show for Lonza Group AG (LZAGF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CHF 3.36B. Against analyst estimates the company has EPS beat 3 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CHF 3.36BCHF 588MCHF 8.40 (diluted)
Q4 FY2025CHF 2.96BCHF 483M-CHF 10.00 (diluted)
Q2 FY2025CHF 3.58BCHF 426MCHF 6.07 (diluted)
Q4 FY2024CHF 3.52BCHF 307MCHF 4.31 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Lonza Group AG (LZAGF)?

Short answer · as of

The distress and quality screens read Altman Z 4.16 · Piotroski F 8. Trailing ratios: ROE 12.9% · ROA 5.4% · current ratio 1.66.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
  • Rich valuation — a P/E of 41.62 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LZAGF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LZAGF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About LZAGF (Healthcare)

These answers are editorial: 1 of these 8 answers is drawn from the LZAGF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is LZAGF a good stock to buy?

Stock Expert AI does not rate LZAGF buy, sell or hold. Lonza Group AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LZAGF stock price today?

The last price recorded for Lonza Group AG (LZAGF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for LZAGF?

Lonza Group AG faces several key risks inherent to its position as a CDMO in the healthcare sector. A primary risk is its reliance on the success and progression of client pipelines; if client drug candidates fail in clinical trials or are deprioritized, Lonza could experience contract cancellations or reduced demand for its manufacturing services.

What are the key factors to evaluate for LZAGF?

Evaluate LZAGF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expansion in Biologics CDMO Services: The global demand for biopharmaceuticals continues to surge, driven by advancements in biotechnology and an aging global population. Not financial advice.

How frequently does LZAGF data refresh on this page?

LZAGF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LZAGF's recent stock price performance?

Lonza Group AG (LZAGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global leadership in contract development and manufacturing for biologics, small molecules, and cell & gene therapies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LZAGF overvalued or undervalued right now?

The trailing P/E of Lonza Group AG (LZAGF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research LZAGF before investing?

Before investing in Lonza Group AG (LZAGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 16 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.